Andreessen Horowitz June 28, 2022
Jennifer Doudna and Vijay Pande

Jennifer Doudna won the 2020 Nobel Prize in Chemistry for her co-discovery of CRISPR/Cas9, a versatile genome editing platform. In the decade since its discovery the toolbox of CRISPR technologies has exploded, acting like rocket fuel for curiosity-driven science. It is also increasingly a foundational technology for many biotech companies.

In this conversation, Doudna chats with a16z general partner Vijay Pande. Previously, he was a Professor at Stanford University, where he directed the Biophysics department. During his time there he also founded the Folding@Home Project and Globavir Biosciences.

Pande and Doudna grapple with questions facing scientists at this inflection point. How do you recognize a discovery that will open further opportunities to engineer biology? What will happen as CRISPR...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Interview / Q&A, Pharma / Biotech, Trends
Former Bristol Myers CEO tapped as Novartis’ next board chair
The Power of Drug Discovery with Philip Tagari
Novartis raises forecasts as top drug sales beat Wall Street estimates
Pharma Pulse 4/23/24: Drug Discount Programs Poised to Change with New Tech, SpecialtyRx Savings Navigator to Enhance Affordability & more
AI Ushers in HPC Revival Says TACC’s Dan Stanzione

Share This Article